Lanxess (LXS) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
17 Nov, 2025Executive summary
Q1 2025 EBITDA pre increased 32% year-over-year to €133 million, reflecting improved utilization, cost savings, and a rebound in Consumer Protection amid a weak market environment.
Net income improved to -€57 million from -€98 million in Q1 2024, supported by better operating performance and Envalior contribution.
Sales remained flat at €1,601 million, with higher volumes offset by lower prices due to raw material cost pass-through.
The divestiture of the Urethane Systems business to UBE was completed earlier than planned, with proceeds to be used for debt reduction and balance sheet strengthening.
Persistently weak market conditions in agrochemicals and construction industries.
Financial highlights
EBITDA pre exceptionals rose 31.7% to €133 million, with margin increasing to 8.3% from 6.3% year-over-year.
Adjusted EPS improved to €0.23 from -€0.09 in Q1 2024.
Capex increased 15% to €45 million.
Free cash flow was -€111 million, impacted by seasonal working capital build-up.
Net financial debt increased seasonally to €2,512 million.
Outlook and guidance
Full-year 2025 EBITDA pre guidance reiterated at €600–650 million, including Q1 Urethane Systems contribution.
Q2 expected to improve sequentially but remain below prior year due to absence of Urethanes contribution.
No major FX headwinds expected due to comprehensive hedging at a rate of around EUR/USD 1.10.
Slight growth anticipated in core and consumer businesses; construction improvement expected from 2026.
Geopolitical tensions and US trade policy create significant market uncertainty.
Latest events from Lanxess
- Earnings rose, costs fell, and sustainability advanced amid global uncertainty and strategic refocus.LXS
AGM 20253 Feb 2026 - Q2 2024 EBITDA pre exceptionals surged 69% year-over-year despite lower sales.LXS
Q2 20241 Feb 2026 - EBITDA pre exceptionals jumped 45% and net income returned to profit in Q3 2024.LXS
Q3 202416 Jan 2026 - EBITDA rose 20% in 2024 as cost savings and portfolio focus drove profitability gains.LXS
Q4 202426 Dec 2025 - Q2 sales and EBITDA fell on weak demand, but net debt dropped after Urethane divestment.LXS
Q2 202523 Nov 2025 - EBITDA pre exceptionals rose 32% in Q1 2025, with guidance confirmed at €600–650 million.LXS
Q1 2025(Media)17 Nov 2025 - Sales and EBITDA fell sharply in Q3 2025, with cost cuts and divestments improving leverage.LXS
Q3 20256 Nov 2025 - Phased exit of JV stake begins, unlocking over €1.2bn in value with EBITDA-linked upside.LXS
Investor Update16 Oct 2025